Braidwell LP Sells 5,500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Braidwell LP trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 364,900 shares of the biotechnology company's stock after selling 5,500 shares during the period. Sarepta Therapeutics makes up 1.3% of Braidwell LP's investment portfolio, making the stock its 28th largest holding. Braidwell LP owned about 0.38% of Sarepta Therapeutics worth $44,368,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Capital International Investors boosted its position in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. Norges Bank bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $126,315,000. Alkeon Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 34.7% in the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock worth $103,819,000 after acquiring an additional 220,000 shares during the last quarter. Brandywine Global Investment Management LLC bought a new position in Sarepta Therapeutics in the 4th quarter valued at about $22,613,000. Finally, Northern Trust Corp lifted its holdings in shares of Sarepta Therapeutics by 22.6% in the fourth quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company's stock valued at $97,699,000 after purchasing an additional 147,874 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on SRPT. Royal Bank of Canada dropped their price objective on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research note on Wednesday. The Goldman Sachs Group cut their price target on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright decreased their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating for the company in a research note on Wednesday. Wells Fargo & Company dropped their target price on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, Evercore ISI lowered Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 target price for the company. in a report on Thursday. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.22.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded down $0.25 during mid-day trading on Friday, hitting $36.27. 6,614,378 shares of the stock traded hands, compared to its average volume of 1,617,527. The business's 50-day moving average price is $66.84 and its 200 day moving average price is $100.86. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market cap of $3.56 billion, a PE ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 12-month low of $35.46 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business's revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. On average, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.